SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

DELEAGE JEAN

(Last)

(First)

(Middle)

ONE EMBARCADERO CENTER SUITE 450

(Street)

SAN FRANCISCO

94111

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IDM PHARMA, INC. [ IDMI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/16/2005

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾⁽²⁾	08/16/2005	⁽³⁾	P/K⁽¹⁾		236,380⁽¹⁾	A	$0⁽¹⁾	236,380⁽¹⁾	I	See footnotes.⁽²⁾⁽⁴⁾⁽⁵⁾
Common Stock⁽¹⁾⁽⁶⁾	08/16/2005	⁽³⁾	P/K⁽¹⁾		134,995⁽¹⁾	A	$0⁽¹⁾	134,995⁽¹⁾	I	See footnotes.⁽⁴⁾⁽⁵⁾⁽⁶⁾
Common Stock⁽¹⁾⁽⁷⁾	08/16/2005	⁽³⁾	P/K⁽¹⁾		8,909⁽¹⁾	A	$0⁽¹⁾	8,909⁽¹⁾	I	See footnotes.⁽⁴⁾⁽⁵⁾⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option⁽⁸⁾	$6.99	08/16/2005	⁽³⁾	A		2,857		09/16/2005⁽⁹⁾	08/15/2015	Common Stock	2,857	$0	2,857	D

Explanation of Responses:

1. The shares of common stock were acquired in an exchange of shares of IDM S.A. for the shares of IDM Pharma, Inc. At the time of the exchange, each share of IDM S.A. was exchanged for 3.771865 shares of IDM Pharma, Inc. common stock, and adjusted for a 1 for 7 reverse stock split of the common stock of IDM Pharma, Inc.

2. The shares are beneficially owned by Alta BioPharma Partners, L.P.

3. N/A

4. Alta Partners ("AP") provides investment advisory services to venture capital funds including Alta BioPharma Partners, L.P. ("ABP"), IDM Chase Partners (Alta Bio), LLC ("Chase") and Alta Embarcadero BioPharma Partners, LLC ("AEBP"). The respective general partner, managing directors, managing member and members of ABP, Chase and AEBP exercise sole voting and investment power with respect to the shares owned by such funds. Certain principals of AP are managing directors of Alta BioPharma Management, LLC (which is the general partner of ABP), members of AEBP and members of Alta/Chase BioPharma Management, LLC (which is the managing member of Chase). As managing directors and members of such entitites, they may be deemed to share voting and investment powers for the shares held by the funds. The principals of AP disclaim beneficial ownership of all such shares held by the foregoing funds except to the extent of their proportionate pecuniary interests therein.

5. Upon the effective date of the share exchange and related transactions, Jean Deleage became a director of IDM Pharma, Inc. Dr. Deleage is a managing director of Alta BioPharma Management, LLC (which is the general partner of Alta BioPharma Partners L.P.("ABP")), a member of Alta Embarcadero BioPharma Partners LLC ("AEBP")and a managing director of Alta/Chase BioPharma Management LLC (Chase) (which is the managing member of IDM Chase Partners (Alta Bio), LLC). As a managing director and member of such entities, he may be deemed to share voting and investment powers over the shares held by such funds. As a principal of Alta Partners, he disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of his proportionate pecuniary interests therein.

6. The shares are beneficially owned by IDM Chase Partners (Alta Bio), LLC.

7. The shares are beneficially owned by Alta Embarcadero BioPharma Partners, LLC.

8. Grant to reporting person of a non-qualified stock option to purchase shares of the common stock of IDM Pharma, Inc. pursuant to the terms of the Company's 2000 Stock Plan.

9. The option vests in forty-eight (48) equal installments over four four years from 08/16/2005, the date of appointment to the Board of Directors. The first installment vests and is exercisable on 09/16/2005, and the option will be fully vested on 08/16/2009.

	Fred Hutton, Controller, by power of attorney	08/18/2005
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.